Daily Endocrinology Research Analysis
Three impactful endocrinology papers span therapeutics, neuroendocrine mechanisms, and prognostication. A phase 2 randomized trial shows that semaglutide doses up to 16 mg/week add modest HbA1c benefit but greater weight loss at the cost of more adverse events. Mechanistic work in Cell identifies hypothalamic PNOC/NPY neurons as key mediators of leptin’s anorectic action, and a large multicenter study validates the PANOMEN-3 model to predict pituitary tumor recurrence.
Summary
Three impactful endocrinology papers span therapeutics, neuroendocrine mechanisms, and prognostication. A phase 2 randomized trial shows that semaglutide doses up to 16 mg/week add modest HbA1c benefit but greater weight loss at the cost of more adverse events. Mechanistic work in Cell identifies hypothalamic PNOC/NPY neurons as key mediators of leptin’s anorectic action, and a large multicenter study validates the PANOMEN-3 model to predict pituitary tumor recurrence.
Research Themes
- GLP-1 receptor agonist dose–response and tolerability in T2D/obesity
- Leptin-regulated hypothalamic circuits controlling energy homeostasis
- Risk stratification and recurrence prediction in pituitary tumors
Selected Articles
1. High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial.
In a blinded phase 2 RCT (n=245), semaglutide 16 mg/week produced only modest additional HbA1c reduction versus 2 mg but achieved greater weight loss (≈4–5 kg more by hypothetical estimand), with higher gastrointestinal adverse events and discontinuations. Findings refine dose–response trade-offs for glycemic vs weight outcomes in T2D with overweight/obesity.
Impact: This rigorous dose-ranging RCT directly informs clinical dosing decisions for semaglutide by quantifying benefits and tolerability at higher doses. It will shape optimization of therapy for patients prioritizing weight loss over incremental glycemic control.
Clinical Implications: For T2D with overweight/obesity, escalating above 2 mg/week may be considered when additional weight loss is prioritized, with counseling on increased GI adverse events and potential discontinuation. The modest HbA1c gain suggests individualized dosing rather than automatic up-titration.
Key Findings
- Semaglutide 16 mg/week vs 2 mg/week yielded modest additional HbA1c reduction (−0.5% by hypothetical estimand; 95% CI −1.0 to −0.1).
- Greater weight loss with 16 mg/week (−4.5 kg by hypothetical estimand; 95% CI −7.6 to −1.4) and dose–response modeling confirmed findings.
- Gastrointestinal adverse events and treatment discontinuations were more frequent at 8 and 16 mg; no severe hypoglycemia was observed.
Methodological Strengths
- Participant- and investigator-blinded, randomized, placebo-controlled phase 2 design with predefined estimands.
- Dose–response modeling corroborated primary analyses.
Limitations
- Phase 2 duration (40 weeks) may not capture long-term safety/tolerability.
- No dose modifications allowed, which may not reflect real-world titration practices.
Future Directions: Head-to-head trials comparing high-dose semaglutide with other anti-obesity agents; pragmatic studies allowing flexible titration; benefit–risk stratification tools integrating patient preferences.
OBJECTIVE: Studies have demonstrated dose-dependent efficacy of glucagon-like peptide 1 receptor agonists for glycemic control and body weight. The aim of this trial was to characterize the dose-dependent effects of semaglutide (up to 16 mg/week) in people with type 2 diabetes and overweight or obesity. RESEARCH DESIGN AND METHODS: In this parallel-group, participant- and investigator-blinded, phase 2 trial, 245 individuals with type 2 diabetes and BMI ≥27 kg/m2 on metformin were randomized to weekly semaglutide (2, 8, or 16 mg s.c.) or placebo for 40 weeks. Doses were escalated every 4 weeks, followed by a maintenance period. Dose modifications were not allowed. Primary and secondary efficacy end points included change from baseline to week 40 in HbA1c and body weight, respectively. RESULTS: Estimated treatment difference between 16 and 2 mg was -0.3 percentage points (%-points) (95% CI -0.7 to 0.2; P = 0.245) for HbA1c change and -3.4 kg (-6.0 to -0.8; P = 0.011) for weight change for the treatment policy estimand and -0.5%-points (-1.0 to -0.1; P = 0.015) and -4.5 kg (-7.6 to -1.4; P = 0.004), respectively, for the hypothetical estimand. Dose-response modeling confirmed these findings. Treatment-emergent adverse events (AEs) and treatment discontinuations due to AEs, primarily gastrointestinal, were more frequent in the semaglutide 8 and 16 mg groups than in the 2 mg group. No severe hypoglycemic episodes were reported. CONCLUSIONS: Higher semaglutide doses for type 2 diabetes and overweight or obesity provide modest additional glucose-lowering effect, with additional weight loss, at the expense of more AEs and treatment discontinuations. A study for evaluating high-dose semaglutide in obesity is currently underway.
2. Hypothalamic PNOC/NPY neurons constitute mediators of leptin-controlled energy homeostasis.
Using neuron-specific genetics and chemogenetics, the study demonstrates that arcuate PNOC neurons require leptin receptor signaling to restrain feeding and body weight. Loss of leptin signaling in PNOC neurons induces NPY upregulation in an Agrp− PNOC subset, and activating PNOC/NPY neurons drives feeding, identifying a discrete leptin-responsive circuit.
Impact: This work pinpoints a defined hypothalamic PNOC/NPY circuit as a mediator of leptin’s anorectic action, advancing mechanistic understanding of energy balance and offering a precise neural target for anti-obesity interventions.
Clinical Implications: While preclinical, identifying PNOC/NPY neurons as leptin-responsive suggests potential targets for neuromodulation or pharmacology in obesity resistant to leptin therapy.
Key Findings
- Leptin receptor deletion in arcuate PNOC neurons causes hyperphagia and obesity; restoration of Lepr in PNOC neurons on a Lepr-null background reduces body weight.
- Lepr inactivation in PNOC neurons increases Npy expression in PNOC neurons that are Agrp-negative, defining a PNOC/NPY subset.
- Chemogenetic activation of PNOC/NPY neurons promotes feeding comparably to activation of all PNOC neurons, identifying a leptin-responsive feeding circuit.
Methodological Strengths
- Neuron-type-specific genetic manipulations (conditional Lepr deletion/restoration) with causal inference.
- Chemogenetic activation to functionally dissect PNOC/NPY subset roles.
Limitations
- Findings are in mouse models; translational relevance to humans remains to be established.
- Behavioral endpoints focus on acute feeding; long-term metabolic outcomes need evaluation.
Future Directions: Map upstream inputs and downstream projections of PNOC/NPY neurons; test neuromodulation and pharmacologic strategies targeting this circuit in obesity models and, ultimately, in humans.
Leptin acts in the brain to suppress appetite, yet the responsible neurocircuitries underlying leptin's anorectic effect are incompletely defined. Prepronociceptin (PNOC)-expressing neurons mediate diet-induced hyperphagia and weight gain in mice. Here, we show that leptin regulates appetite and body weight via PNOC neurons, and that loss of leptin receptor (Lepr) expression in PNOC-expressing neurons in the arcuate nucleus of the hypothalamus (ARC) causes hyperphagia and obesity. Restoring Lepr expression in PNOC neurons on a Lepr-null obese background substantially reduces body weight. Lepr inactivation in PNOC neurons increases neuropeptide Y (Npy) expression in a subset of hypothalamic PNOC neurons that do not express agouti-related peptide (Agrp). Selective chemogenetic activation of PNOC/NPY neurons promotes feeding to the same extent as activating all PNOC
3. Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors.
In 1,143 pituitary tumor patients followed a median 8.8 years, PANOMEN-3 achieved 75.6% accuracy for predicting recurrence/progression in both operated and nonoperated patients. Residual tumor, hereditary syndromes, and active secretory status were the strongest predictors, with risk rising across PANOMEN-3 grades.
Impact: This multicenter validation supports using PANOMEN-3 to guide surveillance intensity and adjuvant therapy decisions in pituitary tumors, moving prognostication beyond single parameters.
Clinical Implications: Clinicians can apply PANOMEN-3 to stratify recurrence risk, emphasizing residual tumor clearance, genetic evaluation for hereditary syndromes, and management of active secretion to mitigate progression.
Key Findings
- In a cohort of 1,143 patients, PANOMEN-3 predicted recurrence/progression with 75.6% diagnostic accuracy (95% CI 0.716–0.796).
- Residual tumor (HR 2.20), hereditary syndrome (HR 5.15), and active secretory status (HR 1.80) were major predictors in multivariate models.
- Recurrence/progression rates increased across PANOMEN-3 grades (2.5%, 10.3%, 33.7%, 33.3%; P < .001).
Methodological Strengths
- Large multicenter cohort with long median follow-up (8.8 years) enabling time-to-event analyses.
- Use of Kaplan–Meier and multivariate Cox regression to quantify prognostic variables.
Limitations
- Retrospective case-control design with potential selection and information bias.
- External generalizability beyond the Spanish population requires further validation.
Future Directions: Prospective, international validation and integration of molecular markers could enhance PANOMEN-3’s predictive performance and clinical utility.
CONTEXT: It has been proposed that the PANOMEN-3 classification may be useful to guide the prognosis and therapy of patients with pituitary tumors (PTs). However, the model has not yet been validated to date in order to assess its usefulness in routine clinical practice. OBJECTIVE: The aim of our study was to validate the classification proposed by the PANOMEN-3 group for the prediction of tumor recurrence/progression in PTs. METHODS: Multicenter national case-control study of patients with PTs followed for at least 5 years. Kaplan-Meier curves were used to assess the time to tumor recurrence/progression. Univariate and multivariate Cox regression analyses were used to estimate the hazard ratio (HR) and prognostic capacity of the classification proposed by the PANOMEN-3 group. RESULTS: A total of 1143 patients were included. Pituitary surgery was performed in 814 patients and the remaining 329 patients were followed with active surveillance or medical treatment. After a median follow-up of 8.8 years (5-29.8), 253 patients experienced tumor recurrence or biochemical/radiological progression and were classified as cases. The other 890 patients were classified as controls. The mean follow-up from PT diagnosis to recurrence was 7.2 ± 5.4 years. The diagnostic accuracy of the PANOMEN-3 model to predict recurrence/progression was 75.6% (95% CI 0.716-0.796). Residual tumor (HR 2.20, P < .001), a hereditary syndrome (HR 5.15, P = .026), and active secretory status (HR 1.80, P = .021) were the most important variables in this model. Recurrence/progression rate increased with increasing PANOMEN-3 grade (2.5% in grade 0; 10.3% in grade 1, 33.7% in grade 2, and 33.3% in grade 3; P < .001). CONCLUSION: The predictive model proposed by the PANOMEN-3 group may be useful to guide the prognosis and therapy of PTs in the Spanish population since it offers a good accuracy to predict tumoral/biochemical recurrence and/or progression in operated and nonoperated patients.